Nanobiotix Reports Q1 2026 Financial and Operational Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Source: NASDAQ.COM
- Strong Financial Position: As of March 31, 2026, Nanobiotix reported cash equivalents of €42.1 million, which are expected to sufficiently cover its working capital needs through 2029, thereby providing a solid financial foundation for future R&D and market expansion.
- Clinical Trial Advancements: The company amended the protocol for its Phase 3 JNJ-1900 study in Cisplatin-ineligible head and neck cancer patients, demonstrating flexibility and adaptability in its treatment approach aimed at improving patient outcomes.
- Promising Efficacy Data: In a small cohort of 7 patients from the Phase 2 JNJ-1900 study for unresectable Stage 3 NSCLC, the overall response rate reached 85.7% following the full treatment regimen of concurrent chemoradiotherapy, JNJ-1900, and Durvalumab, indicating the drug's potential efficacy.
- Response Rate Update: At the 2026 European Society for Radiotherapy and Oncology conference, updated data revealed a complete response rate of 57.1% (4 out of 7 patients), further validating the effectiveness of JNJ-1900 in cancer treatment and potentially laying the groundwork for future clinical applications.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NBTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NBTX
Wall Street analysts forecast NBTX stock price to fall
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 35.330
Low
3.50
Averages
3.50
High
3.50
Current: 35.330
Low
3.50
Averages
3.50
High
3.50
About NBTX
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nanobiotix Reports Q1 2026 Financial and Operational Update
- Strong Financial Position: As of March 31, 2026, Nanobiotix reported cash equivalents of €42.1 million, which are expected to sufficiently cover its working capital needs through 2029, thereby providing a solid financial foundation for future R&D and market expansion.
- Clinical Trial Advancements: The company amended the protocol for its Phase 3 JNJ-1900 study in Cisplatin-ineligible head and neck cancer patients, demonstrating flexibility and adaptability in its treatment approach aimed at improving patient outcomes.
- Promising Efficacy Data: In a small cohort of 7 patients from the Phase 2 JNJ-1900 study for unresectable Stage 3 NSCLC, the overall response rate reached 85.7% following the full treatment regimen of concurrent chemoradiotherapy, JNJ-1900, and Durvalumab, indicating the drug's potential efficacy.
- Response Rate Update: At the 2026 European Society for Radiotherapy and Oncology conference, updated data revealed a complete response rate of 57.1% (4 out of 7 patients), further validating the effectiveness of JNJ-1900 in cancer treatment and potentially laying the groundwork for future clinical applications.
See More
Nanobiotix Completes €86.1 Million Follow-On Offering
- Successful Follow-On Offering: Nanobiotix completed a follow-on offering in May 2026, raising approximately €86.1 million, which will be utilized to accelerate the development of the company's other platforms, thereby enhancing its competitive edge in the biotechnology sector.
- Clinical Trial Progress: At the 2026 Annual Meeting of the European Society for Radiotherapy and Oncology, preliminary efficacy data for JNJ-1900 (NBTXR3) in patients with unresectable Stage 3 non-small cell lung cancer was presented, showing an overall response rate of 85.7%, indicating the drug's potential clinical value.
- FDA Protocol Amendment: The FDA has accepted a protocol amendment for the NANORAY-312 study, eliminating the previously planned interim analysis and modifying the final analysis to be conducted sooner with fewer events, aimed at expediting the research process.
- Strong Financial Position: As of March 31, 2026, the company reported cash and cash equivalents of €42.1 million, and combined with the proceeds from the follow-on offering, it expects to support operations into 2029, ensuring financial stability.
See More
Nanobiotix Joins Euronext Tech Leaders Index, Enhancing Visibility
- Industry Recognition: Nanobiotix's inclusion in the Euronext Tech Leaders Index signifies its innovative progress at the intersection of nanotechnology and medicine, which is expected to attract more international investor attention.
- Market Impact: CEO Laurent Levy stated that this recognition reflects not only the company's growth but also the potential of physics-based innovation to contribute to future treatment solutions, potentially driving the development of new therapies.
- Investor Network: Launched in 2022, the Euronext Tech Leaders initiative aims to enhance the international visibility of high-growth tech companies, and Nanobiotix's membership will provide access to a broader network of market participants and support for long-term growth.
- Technology Platforms: Nanobiotix holds over 30 patents related to its three nanotechnology platforms, which address significant medical needs in oncology and central nervous system disorders, positioning the company to leverage these technologies for future advancements.
See More
Nanobiotix Completes $100 Million Global Offering
- Expanded Financing: Nanobiotix S.A. announced that underwriters fully exercised their option to purchase additional American Depositary Shares (ADS), bringing the total gross proceeds from the global offering to $100 million, reflecting strong market confidence in the company's business.
- Share Issuance Details: The global offering issued a total of 2,218,467 ordinary shares, including 259,178 shares in the form of ADS and 345,099 pre-funded warrants, further strengthening the company's capital base.
- Planned Use of Funds: The company stated that 10% of the proceeds will be used to advance JNJ-1900, a novel radio enhancer targeting solid tumors, while 50%-60% will be allocated to developing its Nanoprimer platform, and 30%-40% for general corporate purposes, ensuring effective fund allocation.
- Financial Health Outlook: The proceeds from this offering are expected to be sufficient to support the company's operations into 2029, indicating financial stability and growth potential in the coming years.
See More
Nanobiotix Completes $100 Million Global Offering
- Expanded Financing: Nanobiotix announced that underwriters fully exercised their option to purchase an additional 33,805 ordinary shares, bringing the total gross proceeds of the global offering to approximately $100 million, reflecting strong market confidence in its biotech innovations.
- Pricing Strategy: The subscription price of €33.60 per ordinary share, representing a 14.92% discount and aligning with the volume-weighted average price over the last three trading days, enhances investor appeal and strengthens the company's competitive position in the capital markets.
- Planned Use of Proceeds: The company intends to allocate 50-60% of the net proceeds to advance the development of Nanoprimer and other platforms, with 30-40% earmarked for general corporate purposes, demonstrating a strategic focus on future growth.
- Financial Stability Outlook: Nanobiotix expects the proceeds from this offering to support its working capital needs through 2029, indicating a healthy financial status and sustainable growth potential in the current market environment.
See More
Nanobiotix Resumes Trading and Global Offering
- Trading Resumption: Nanobiotix S.A. resumed trading of its ordinary shares on Euronext Paris at 3:30 p.m. Paris time on May 21, 2026, after a temporary halt requested by the company to confirm investor allocations and pricing.
- Global Offering Context: The resumption is linked to the company's previously announced global offering, which includes a U.S. public offering of American Depositary Shares (ADSs) and ordinary shares along with pre-funded warrants for qualified investors in Europe and other countries, indicating an active capital market strategy.
- Company Overview: Founded in 2003 and headquartered in Paris, Nanobiotix has been listed on Euronext since 2012 and on the Nasdaq Global Select Market since 2020, holding over 25 patent families focused on oncology and central nervous system disorders.
- Stock Price Fluctuation: Over the past year, NBTX's stock has fluctuated between $3.66 and $57.14, currently trading at $41.79, down 3.17%, reflecting market caution regarding its future performance.
See More
Nanobiotix Reports Q1 2026 Financial and Operational Update
- Strong Financial Position: As of March 31, 2026, Nanobiotix reported cash equivalents of €42.1 million, which are expected to sufficiently cover its working capital needs through 2029, thereby providing a solid financial foundation for future R&D and market expansion.
- Clinical Trial Advancements: The company amended the protocol for its Phase 3 JNJ-1900 study in Cisplatin-ineligible head and neck cancer patients, demonstrating flexibility and adaptability in its treatment approach aimed at improving patient outcomes.
- Promising Efficacy Data: In a small cohort of 7 patients from the Phase 2 JNJ-1900 study for unresectable Stage 3 NSCLC, the overall response rate reached 85.7% following the full treatment regimen of concurrent chemoradiotherapy, JNJ-1900, and Durvalumab, indicating the drug's potential efficacy.
- Response Rate Update: At the 2026 European Society for Radiotherapy and Oncology conference, updated data revealed a complete response rate of 57.1% (4 out of 7 patients), further validating the effectiveness of JNJ-1900 in cancer treatment and potentially laying the groundwork for future clinical applications.
See More
Nanobiotix Completes €86.1 Million Follow-On Offering
- Successful Follow-On Offering: Nanobiotix completed a follow-on offering in May 2026, raising approximately €86.1 million, which will be utilized to accelerate the development of the company's other platforms, thereby enhancing its competitive edge in the biotechnology sector.
- Clinical Trial Progress: At the 2026 Annual Meeting of the European Society for Radiotherapy and Oncology, preliminary efficacy data for JNJ-1900 (NBTXR3) in patients with unresectable Stage 3 non-small cell lung cancer was presented, showing an overall response rate of 85.7%, indicating the drug's potential clinical value.
- FDA Protocol Amendment: The FDA has accepted a protocol amendment for the NANORAY-312 study, eliminating the previously planned interim analysis and modifying the final analysis to be conducted sooner with fewer events, aimed at expediting the research process.
- Strong Financial Position: As of March 31, 2026, the company reported cash and cash equivalents of €42.1 million, and combined with the proceeds from the follow-on offering, it expects to support operations into 2029, ensuring financial stability.
See More
Nanobiotix Joins Euronext Tech Leaders Index, Enhancing Visibility
- Industry Recognition: Nanobiotix's inclusion in the Euronext Tech Leaders Index signifies its innovative progress at the intersection of nanotechnology and medicine, which is expected to attract more international investor attention.
- Market Impact: CEO Laurent Levy stated that this recognition reflects not only the company's growth but also the potential of physics-based innovation to contribute to future treatment solutions, potentially driving the development of new therapies.
- Investor Network: Launched in 2022, the Euronext Tech Leaders initiative aims to enhance the international visibility of high-growth tech companies, and Nanobiotix's membership will provide access to a broader network of market participants and support for long-term growth.
- Technology Platforms: Nanobiotix holds over 30 patents related to its three nanotechnology platforms, which address significant medical needs in oncology and central nervous system disorders, positioning the company to leverage these technologies for future advancements.
See More
Nanobiotix Completes $100 Million Global Offering
- Expanded Financing: Nanobiotix S.A. announced that underwriters fully exercised their option to purchase additional American Depositary Shares (ADS), bringing the total gross proceeds from the global offering to $100 million, reflecting strong market confidence in the company's business.
- Share Issuance Details: The global offering issued a total of 2,218,467 ordinary shares, including 259,178 shares in the form of ADS and 345,099 pre-funded warrants, further strengthening the company's capital base.
- Planned Use of Funds: The company stated that 10% of the proceeds will be used to advance JNJ-1900, a novel radio enhancer targeting solid tumors, while 50%-60% will be allocated to developing its Nanoprimer platform, and 30%-40% for general corporate purposes, ensuring effective fund allocation.
- Financial Health Outlook: The proceeds from this offering are expected to be sufficient to support the company's operations into 2029, indicating financial stability and growth potential in the coming years.
See More
Nanobiotix Completes $100 Million Global Offering
- Expanded Financing: Nanobiotix announced that underwriters fully exercised their option to purchase an additional 33,805 ordinary shares, bringing the total gross proceeds of the global offering to approximately $100 million, reflecting strong market confidence in its biotech innovations.
- Pricing Strategy: The subscription price of €33.60 per ordinary share, representing a 14.92% discount and aligning with the volume-weighted average price over the last three trading days, enhances investor appeal and strengthens the company's competitive position in the capital markets.
- Planned Use of Proceeds: The company intends to allocate 50-60% of the net proceeds to advance the development of Nanoprimer and other platforms, with 30-40% earmarked for general corporate purposes, demonstrating a strategic focus on future growth.
- Financial Stability Outlook: Nanobiotix expects the proceeds from this offering to support its working capital needs through 2029, indicating a healthy financial status and sustainable growth potential in the current market environment.
See More
Nanobiotix Resumes Trading and Global Offering
- Trading Resumption: Nanobiotix S.A. resumed trading of its ordinary shares on Euronext Paris at 3:30 p.m. Paris time on May 21, 2026, after a temporary halt requested by the company to confirm investor allocations and pricing.
- Global Offering Context: The resumption is linked to the company's previously announced global offering, which includes a U.S. public offering of American Depositary Shares (ADSs) and ordinary shares along with pre-funded warrants for qualified investors in Europe and other countries, indicating an active capital market strategy.
- Company Overview: Founded in 2003 and headquartered in Paris, Nanobiotix has been listed on Euronext since 2012 and on the Nasdaq Global Select Market since 2020, holding over 25 patent families focused on oncology and central nervous system disorders.
- Stock Price Fluctuation: Over the past year, NBTX's stock has fluctuated between $3.66 and $57.14, currently trading at $41.79, down 3.17%, reflecting market caution regarding its future performance.
See More
